Incorporating CDK4/6 Inhibitors in the Treatment of Advanced Luminal Breast Cancer.

ABSTRACT: After optimizing endocrine monotherapy modalities in the setting of advanced luminal breast cancer (BC), dual endocrine/targeted therapy combinations have been tested with positive results, and are transforming this BC subtype treatment landscape. Cell cycle deregulation is a hallmark of cancer that has become a key druggable target in hormone receptor (HR)-positive BC due to its role in endocrine resistance mechanisms. Cyclin dependent kinase (CDK)4/6 inhibitors have experienced a fast development in combination with endocrine therapy and have already been commercialized in some countries. In this review, we will summarize the development of these CDK4/6 inhibitors in luminal BC, from the preclinical data to the pivotal phase III trials that led to their approval, focusing on the efficacy

SUBMITTER: Echavarria I 

PROVIDER: S-EPMC5704690 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature